Drug intelligence / Profile preview

LiangxueTuiZi Formula

Development stage: Preclinical
Lead developer: Henan Science and Technology Department
Administration: Oral

Overview

LiangxueTuiZi Formula is a Traditional Chinese Medicine (TCM) formula currently under investigation as an intervention for Henoch-Schönlein purpura. It is specifically administered to patients classified within the 'Blood heat group' syndrome of the disease. This formula is being studied in clinical trials by institutions including the Key Project of He'nan Science and Technology Department and The First Affiliated Hospital of He'nan University of Chinese Medicine.

Other names: 凉血退紫方

Beyond the preview

Go deeper on LiangxueTuiZi Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiangxueTuiZi Formula.

Explore the full profile